Open House Original Discount Contracts 2025-17 - Beclometason, Formoterol, Glycopyrronium (ATC: R03AL09)
Original notice title
Germany – Pharmaceutical products – Open House Originale Rabattverträge 2025-17 - Beclometason, Formoterol, Glycopyrronium (Wirkstoffkombination) ATC: R03AL09
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated contract value provided; potential revenue cannot be assessed.
Contract terminates automatically upon patent expiry or loss of market exclusivity, which could shorten contract durati...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications
Tender facts
- Contracting authority
- Techniker Krankenkasse
- Country
- Germany
- CPV
- 33600000 - Pharmaceutical products
- Deadline
- Jun 29, 2027
Overview
Moderate opportunityKey Facts
- Supplies contract
- 1 lot
- Duration until Jun 2027
- Supply of pharmaceutical products containing active ingredient combination Beclometason, Formoterol, Glycopyrronium (ATC: R03AL09)
- Nationwide delivery in Germany
Show full summary
Open House procedure (non-procurement) by Techniker Krankenkasse and associated health insurers for discount contracts (Rabattverträge) for the active ingredient combination Beclometason, Formoterol, Glycopyrronium (ATC: R03AL09). The contract is a supply of pharmaceutical products. No estimated value provided. Contract duration max 24 months from 01.07.2025 to 30.06.2027. Participation possible anytime during the contract period. Submission by email (with qualified electronic signature) or post. No exclusivity.
Risks
No estimated contract value provided; potential revenue cannot be assessed.
Contract terminates automatically upon patent expiry or loss of market exclusivity, which could shorten contract durati...
Analysis may be incomplete
Only part of the procurement documentation was analyzed. Additional eligibility requirements, certificates, or submission documents may exist in the remaining tender documentation.
Key Requirements
Technical
- Must be a pharmaceutical entrepreneur (pharmazeutischer Unternehmer) as per §4 Abs. 18 AMG
- Must hold a valid marketing authorization for the specific drug combination or be entitled to market it
Eligibility
- Must submit a self-declaration (Anlage 4) confirming eligibility and reliability
Requirements may be incomplete.
Award Criteria
Lot 1
Buyer
Location
Hamburg, DEU
Website
Identifier
992-80116-93
Activity
Health
Lots (1)
LOT-0001
Open House Original Discount Contracts 2025-17 - Beclometason, Formoterol, Glycopyrronium (ATC: R03AL09)
Discount contracts for the active ingredient combination Beclometason, Formoterol, Glycopyrronium (ATC: R03AL09) nationwide in Germany.
Location
Duration
Category
Award Criteria
Deadline
Award details
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zur Wirkstoffkombination Beclometason, Formoterol, Glycopyrronium (ATC: R03AL09) zu schließen.
Value note
Show original TED data
Original lot title
Open House Originale Rabattverträge 2025-17 - Beclometason, Formoterol, Glycopyrronium (Wirkstoffkombination) ATC: R03AL09
Original TED description
Die TK verfolgt das Ziel, mit allen geeigneten pharmazeutischen Unternehmern Rabattverträge nach § 130a Abs. 8 SGB V zur Wirkstoffkombination Beclometason, Formoterol, Glycopyrronium (ATC: R03AL09) zu schließen.
Procurement Details
- Publication date
- 22 May 2025
- Languages
- German
Reference metadata
- Legal basis
- 32014L0024
Reference IDs
- Tender ID
- 332579-2025
Documents (1)
Similar tenders
Bulgaria – Pharmaceutical products – Динамична система за покупки за доставка на лекарствени продукти за Медицински институт на МВР
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Oralair(R) (ATC-Code nach WHO: V01AA02)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells zum Wirkstoff Ipratropiumbromid (ATC-Code nach WHO: R03BB01)
Germany – Pharmaceutical products – Abschluss nicht exkl. Arzneimittel-Rabattvereinb. nach § 130a Abs. 8 SGB V im Wege eines Open-House-Modells über Arzneimittel mit dem Handelsnamen Orylmyte(R) (ATC-Code nach WHO: V01AA03)
Germany – Pharmaceutical products – Abschluss nicht-exklusiver Rabattvereinbarungen nach § 130a Abs. 8 SGB V zu den genannten Wirkstoffen mit Abschlussmöglichkeit im Rahmen des sogenannten Open-House-Verfahrens.
Germany – Pharmaceutical products – Open House Biologika Rabattverträge 2026 - 27 - Follitropin delta
Opportunity Score
Why this score?
Opportunity
50 / 100
Complexity
30 / 100
Risk factors
No estimated contract value provided; potential revenue cannot be assessed.
Contract terminates automatically upon patent expiry or loss of market exclusivity, which could shorten contract durati...
Deep Portfolio Analysis
Uses:
- Description
- Industries & Services
- Capabilities
- Market & Experience
- Certifications